Introduction
The notion that variations in host response to infection might have a genetic basis is not new. Early experiences of the use of malaria to treat syphilis, or the accidental administration of Mycobacterium tuberculosis to a population in Germany, were both associated with a remarkable variation in individual response. 1 But it was not until the late 1940s, and through the remarkable insight of JBS Haldane, that a plausible genetic protective mechanism was first postulated.
At the 8th International Congress of Genetics in Stockholm in 1948 Neel and Valentine, in order to explain the remarkably high frequencies of thalassaemia in some of the immigrant populations in the USA, calculated a mutation rate for the disease of 1:2500. Haldane felt that this was unlikely and that these remarkable gene frequencies must be the result of heterozygote selection. ' The corpuscules of anaemic heterozygotes are smaller than normal, and more resistant to hypertonic solutions. It is at least conceivable that they are also more resistant to attacks by the sporozoa which cause malaria, a disease prevalent in Italy, Sicily and Greece, where the gene is frequent %'. 2 Although it has been suggested that the concept of genetic resistance to infection was already established by the late 1940s, 3 a recent reassessment of this question leaves little doubt of the originality and importance of what became known as the 'malaria hypothesis'. 4 This review focuses on the mechanisms that underlie genetic resistance to malaria and briefly summarises 
Malaria
Of more than 100 species of malarial parasite (Plasmodium), there are only four that have man as their natural vertebrate host; P. falciparum, P. malariae, P. vivax and P. ovale. Because malaria has in the past and continues to be one of the major killers of mankind, information about individual genetic susceptibility is of broad biological interest. However, with the advent of potential vaccines against malarial infection, and the problems of testing their efficacy in the field, it now becomes of considerable practical importance to be able to determine the frequency and degree of natural protection. Over recent years a considerable amount of progress has been made towards this end.
Inherited disorders of haemoglobin
Collectively, the inherited disorders of haemoglobin are the commonest monogenic diseases in man. They comprise the structural haemoglobin variants and the thalassaemias, inherited defects in the synthesis of the ␣ or ␤ chains of human adult haemoglobin. Although hundreds of structural haemoglobin variants have been identified, 5 only three, Hbs S, C and E, reach polymorphic frequencies. 6, 7 The gene for Hb S is distributed widely throughout sub-Saharan Africa, the Middle East and parts of the Indian sub-continent, where carrier frequencies range from 5 to 40% or more of the population. Hb C is restricted to parts of West and North Africa. Hb E is found in the eastern half of the Indian sub-continent and throughout Southeast Asia, where, in some areas, carrier rates may exceed 60% of the population. The thalassaemias have a high incidence in a broad band extending from the Mediterranean basin and parts of Africa, throughout the Middle East, the Indian subcontinent, Southeast Asia, Melanesia and into the Pacific Islands. 4, 7 The carrier frequencies for ␤-thalassaemia in these areas range from 1 to 20%, though rarely greater, while those for the milder forms of ␣ thalassaemia are much higher, ranging from 10 to 20% in parts of subSaharan Africa, through 40% or more in some Middle Eastern and Indian populations, to as high as 80% in northern Papua New Guinea and isolated groups in northeast India.
Analysis of these conditions at the molecular level has provided invaluable information about their heterogeneity and population genetics. Studies of globin-gene haplotypes, that is the patterns of restriction fragmentlength polymorphisms in the ␣-or ␤-globin-gene clusters associated with these conditions, [8] [9] [10] has provided important information about their evolution.
11 They suggest that the sickle cell mutation may have occurred at least twice, once in Africa and once in either the Middle East or India. Similar data have been interpreted as pointing to multiple origins for the Hb S gene in Africa and the Hb E gene in Asia. This seems unlikely however, and a more plausible explanation for much of the haplotype diversity observed in association with these variants is that it reflects redistribution on different backgrounds by gene conversion and recombination. 11 Over 200 different mutations have been found to underlie ␤-thalassaemia; each high-frequency population has its own particular mutations. 4, 12 The genetics of ␣-thalassaemia is more complex, particularly since the ␣-globin genes are duplicated. 4 There are two major forms of ␣ thalassaemia, ␣ othalassaemia in which both linked ␣-globin genes are deleted, and ␣ + -thalassaemia in which one of the pair of linked genes is deleted. The homozygous states for these conditions are represented as --/--and -␣/-␣. Both these conditions are extremely heterogeneous at the molecular level and many different size deletions have been found to cause both ␣ + -and ␣ o -thalassaemia. As in the case of ␤-thalassaemia, the high-frequency regions for ␣-thalassaemia have different sets of mutations. 4, 12 The extensive evidence which indicated that the sickle cell trait offers protection against P. falciparum malaria has been reviewed previously. 11, 13 More recent studies in West Africa suggest that the greatest impact of Hb S seems to be to protect against either death or severe disease, that is profound anaemia or cerebral malaria, while having less effect on infection per se. 14 The mechanism for its protective effects have also been reviewed recently and probably reflect both impaired entry into, and growth of parasites in, red cells. 1, 4 Recent studies in West Africa suggest that the relatively high frequencies of Hb C have also been maintained by resistance to P. falciparum malaria. 15 In this case there is evidence both for heterozygote and homozygote resistance and the authors suggest that, unlike the sickle cell mutation, this may be an example of transient polymorphism, based largely on the perceived lack of clinical disability or haematological changes of Hb C homozygotes. However, if this were the case it is difficult to understand why the frequency of Hb C is not higher in African populations. Since it is not absolutely clear whether homozygotes for this variant are completely unaffected by the condition, further work will be required to substantiate this interesting suggestion. To date, there is no formal evidence for the protective effect of Hb E against malaria, although its population distribution and phenotypic properties of a mild form of ␤-thalasssaemia suggest that this is very likely to be the case. 4 Curiously, it has taken much longer to provide any solid backing for Haldane's original hypothesis that thalassaemia carriers are protected against malaria. This long and frustrating story has been reviewed recently. 4 While early studies in Sardinia suggested that there was a relationship between the distribution of thalassaemia and malaria in the past, this correlation was not observed in other populations. Furthermore, until the molecular era, it was almost impossible to distinguish between selection, drift, migration of founder effects as the basis for the population distribution of the thalassaemias. However, once it became apparent that each high-frequency area has its own particular thalassaemia mutations it seemed more likely that they had arisen independently and then expanded due to local selective pressures. More recent studies have provided strong evidence that this is the case, at least for the ␣-thalassaemias.
The frequency of ␣ + -thalassaemia in the Southwest Pacific follows a clinal distribution from north/west to south/east, with the highest frequencies on the north coast of New Guinea and the lowest in New Caledonia. 16 These frequencies show a strong correlation with malaria endemicity, as recorded in pre-eradication surveys. On the other hand, there is no geographical correlation of malarial endemicity with other polymorphic markers in this region. The possibility that ␣-thalassaemia had been introduced from the mainland populations of Southeast Asia, and that its frequency had been diluted as they moved south across the island populations, was excluded when it was found that the molecular forms of ␣-thalassaemia in Melanesia and Papua New Guinea are different to those of the mainland and are set in different ␣-globin gene haplotypes. 16 Although these findings provided strong circumstantial evidence that the high frequency of ␣-thalassaemia in the Southwest Pacific is the result of malarial selection, it was also found that the disease occurs with gene frequencies varying from 1 to 15% elsewhere in this region, from Fiji in the west to Tahiti and beyond in the east, and in the Micronesian atolls. This was worrying because malaria has never been recorded in these island populations. However, further studies showed that in Polynesia almost 100% of ␣ + -thalassaemia can be accounted for by a single mutation which had been previously defined in Vanuatu. Furthermore, this mutation was on the common Vanuatuan ␣-globin gene haplotype. These observations provided strong evidence that the occurrence of the ␣-thalassaemia gene in these non-malarious areas was the result of population migration. 17 These population studies suggesting a protective effect of ␣ thalassaemia against P. falciparum malaria have been augmented more recently by a prospective case-control study of nearly 250 children with severe malaria admitted to Madang Hospital on the north coast of Papua New Guinea, a region where there is a very high rate of malaria transmission. Compared with normal children, the risk of contracting severe malaria, as defined by the strictest WHO guidelines, was 0.4 for ␣ + -thalassaemia homozygotes, and 0.66 for ␣ + -heterozygotes. These studies provide direct evidence for a very strong protective effect of ␣ + -thalassaemia against malaria, both in the heterozygous and homozygous state. 18 Molecular analyses of the ␤-globin genes in thalassaemic and non-thalassaemic individuals in different populations have provided some, albeit indirect, evidence that ␤-thalassaemia has also arisen from selection. 4 As already mentioned, every population has a different set of ␤-thalassaemia mutations. The ␤-globin gene haplotype distribution is divided into two regions, the 3Ј and 5Ј sub-haplotypes, which are separated by a recombination hotspot. 8, 19 However, it turns out that particular ␤-thalassaemia mutations are closely associated with specific ␤-globin gene haplotypes, most strongly with the 3Ј sub-haplotype which contains the ␤-globin gene, but also with substantial linkage to the 5Ј sub-haplotype, despite the fact that the haplotypes are separated by the hotspot. 9, 11 These observations suggest that a recent cause is responsible for the expansion of the ␤-thalassaemia mutations; migration has not had sufficient time to disperse them unlike the normal ␤-globin gene background haplotypes, nor has recombination yet disrupted these linkages. 4, 11, 20 An excellent example of this relationship is seen in Vanuatu, where the sequences of a 3-kb region around the ␤-gene from 60 normal chromosomes showed 17 different alleles, involving 19 polymorphic sites. In contrast, 12 ␤-thalassaemia chromosomes carrying the common mutation in that region were totally monomorphic over the same region. 21 It seems clear therefore that the ␤-thalassaemia genes throughout malarial regions of the world have been amplified to a high frequency so recently that none of the other forces, migration, recombination, drift, and so on, have had sufficient time or opportunity to bring them into genetic equilibrium with their haplotype backgrounds.
But although these recent studies have provided very strong evidence that the thalassaemias have reached their current frequencies by heterozygote selection against malaria, less progress has been made towards an understanding of the likely mechanisms involved. The extensive literature reporting in vitro studies of invasion and development of P. falciparum in thalassaemic red cells has been reviewed recently. 4 In short, although some abnormalities have been found in the more complex haemoglobinopathies, in the milder forms, that is those which would have had to come under selection to maintain high gene-frequencies, no abnormalities of invasion or growth have been reported. Although several attempts have been made to monitor parasite growth over a number of cycles, these studies have given inconsistent results. More consistent findings have been obtained in analyses of the binding of malaria hyperimmune serum to the surface of P. falciparum-infected thalassaemic red cells, in which it has been found consistently that infected cells bind significantly more antibody per unit area than control cells.
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While there is good evidence that the rate of decline of Hb F production in heterozygous ␤-thalassaemic infants is retarded, 4 and some limited evidence from short-term culture experiments that Hb F retards the growth and development of malarial parasites in vitro, 23 this form of protection would only be applicable to ␤-thalassaemia.
A completely different mechanism for the possible protection against malaria afforded by ␣-thalassaemia was suggested by studies of a large cohort of children, with and without thalassaemia, on an island with holoendemic malaria in Vanuatu. It was found that the incidence of uncomplicated malaria and the prevalence of splenomegaly, an index of malaria infection, was significantly
Genes and Immunity higher in very young children with ␣-thalassaemia than in normal children. Moreover, the effect was most marked in the youngest children and with the non-lethal parasite, P. vivax. 24 It was suggested that the early susceptibility to P. vivax, which may reflect the more rapid turnover of red cells in ␣ thalassaemic infants, 25 may be acting as a natural vaccine by inducing cross-species protection against P. falciparum.
There are other hints that protection by thalassaemia may have at least some degree of immunological involvement. As mentioned earlier, the surface antigen expression in P. falciparum-infected ␣-thalassaemic red cells is almost twice that of normal cells, a phenomenon which may lead to better presentation of parasite antigens to the immune system. Furthermore, rosette formation, which has been associated with cerebral malaria, appears to be reduced in thalassaemic red cells. 26 But perhaps the most important piece of indirect evidence comes from the case-control study described earlier, which revealed that ␣-thalassaemia not only protects against severe malaria, but almost equally against hospitalisation from other infectious diseases. 18 In short, although there are now extensive data in support of Haldane's hypothesis that the high frequencies of thalassaemia have been maintained by heterozygote or, as it now appears, for some forms of mild homozygote advantage against malaria, the mechanisms involved are far more complex than those that he proposed. It is now clear that it is not simply the properties of the smaller, under haemoglobinised red cells that are responsible for the protective effect. Rather, it appears to reflect a much more complex series of events, at least some of which may turn out to have an immunological basis.
Other red cell polymorphisms
It has been believed for a long time that the high prevalence of individuals in Africa who do not carry the Duffy blood group antigen reflects the protective effect of this genotype against infection with P. vivax. This variant disrupts the Duffy antigen/chemokine receptor (DARC) promoter and alters a GATA-1-binding site, which inhibits DARC expression on red cells and therefore prevents DARC-mediated entry of P. vivax. 27, 28 This is a milder form of malaria, at least at the present time, and unless it was more severe in the past there may be another explanation for the high prevalence of those who do not carry the Duffy antigen in African populations. A variety of other milder associations between blood group antigens and susceptibility to malaria have been reported. 29 There is very strong evidence that glucose-6-phosphate dehydrogenase (G6PD) deficiency, an X-linked disorder which affects millions of individuals in tropical countries, is also protective against P. falciparum malaria. Like the thalassaemias, several hundred different mutations are responsible for this condition and their pattern varies between different populations. 30 Both hemizygous males and heterozygous females have been found to be protected against severe malaria in both East and West Africa, 31 and distribution studies, in Vanuatu for example, 32 have shown a strong correlation with malaria. As is the case for the thalassaemias, the mechanisms of protection are still not clear. Work in this field has been reviewed recently; the most likely protective mechanisms appear to be impaired parasite growth or more efficient phagocytosis of parasitised red cells at an early stage of maturation. 1 Another remarkable example of a malaria-related balanced polymorphism involves the mutation in band 3 of the red cell membrane that causes the Melanesian form of ovalocytosis, a condition which is extremely common throughout Melanesia and which appears to be lethal in homozygotes. 33 This is a particularly interesting polymorphism because heterozygotes appear to be fully susceptible to malarial infection and yet are offered almost complete protection against the development of cerebral malaria. 34, 35 This observation suggests that the defect in the red cell membrane also alters the interactions between the parasitised cell and the vascular endothelium. The nature of this interaction remains to be characterised.
Human leukocyte antigen (HLA) genes
The human major histocompatibility complex is the most polymorphic region of the human genome which has been analysed in detail to date. There is increasing evidence that selective pressure by infectious diseases has contributed to this remarkable degree of variability. Structural analyses have suggested that these polymorphisms predominantly affect sites which are critical for peptide epitope binding. 1 In the case of malaria there is strong evidence for associations between both HLA Class I and II alleles and susceptibility to P. falciparum malaria. Thus, at least in parts of Africa the Class I B53 allele and Class II DRB1* 1352 provide considerable resistance against the severe manifestations of malaria, that is profound anaemia and cerebral malaria. 14 Further studies have identified a peptide from the parasite liver-stage antigen-1 (LAS-1) which is an epitope for specific CD8 + cytotoxic T lymphocytes (CTL) that lyse target cells expressing this antigen. 36 These observations suggest that parasite-specific CTL are present after natural infection and that this may be at least one mechanism for the HLA-B53 association. So far, data of this type are lacking for other populations.
Other polymorphisms
After the early successes in identifying polymorphic systems that modify host responses to malaria, a number of other unrelated polygenes that have a similar effect were found. Tumour necrosis factor-␣ (TNF-␣), a cytokine which is secreted by white blood cells and has widespread effects on immune activation, has been analysed in a number of studies. Several different polymorphisms in the promoter regions of the gene for TNF-␣ have been identified and have been associated with particularly severe forms of malaria. 37 One of these, TNF-␣-308, may cause increased expression of TNF-␣. 38 Another influences transcription-factor binding and is associated with an increased risk of cerebral malaria. 39 Another particularly fruitful area of recent research in this field is the investigation of polymorphisms of molecules which are involved in the adhesion of parasitised red cells to the vascular endothelium. The observation that CD36, an important molecule of this kind, is common in Africa led to investigations into its role in malaria.
CD36 deficiency has been associated with both susceptibility and resistance to severe forms of malaria. 40, 41 Recently, a variant of the intracellular adhesion molecule 1 (ICAM1), ICAM Kilifi , has been found more commonly in Kenyan children with severe malaria, although it is not associated with more severe disease in West Africans. 42, 43 Thus although these relationships need a great deal more work, it seems likely that genetic variation of both effectors of the immune system and adhesion molecules may play an important role in variable response to P. falciparum malaria.
Further evidence that there may be hitherto unidentified immune mechanisms responsible for variations in individual response to P. falciparum malaria have come from extensive population studies in West Africa. Analyses of sympatric ethnic groups with very similar exposures to malaria have shown remarkable differences in infection rates, malaria morbidity, and the prevalence and levels of antibodies to a variety of P. falciparum antigens. 44 Extensive investigation of these populations showed no differences in the use of malaria protective measures or any other sociocultural or environmental factors that might have modified these responses.
Murine models of malaria
The growing evidence that at least part of the geneticallydetermined variation in response to severe malaria in humans has an immune basis suggests that more loci which mediate responses of this kind remain to be discovered. So far, total-genome searches for putative loci of this kind have not been reported in the case of human malaria. However, there is growing evidence that analyses of murine malaria using this approach may be of considerable value for further clarifying the genes involved in humans.
Among the murine malaria models, P. chabaudi offers a valuable experimental model of the human form of malaria. Affected animals have analogous blood-stage antigens, the organism invades reticulocytes and mature erythrocytes, infection is associated with suppression of B-and T-cell responses, and the parasite is sequested in the liver and spleen. Recently, there has been considerable success in starting to identify some of the loci involved in variable susceptibility to the consequences of P. chabaudi-induced malaria in different strains of mice. These studies have involved the identification of resistant strains by cross-breeding and then using total genome searches to identify the loci involved in reduced susceptibility. [45] [46] [47] Using this approach a number of chromosomal regions in the mouse genome have been pinpointed as likely to contain a resistance loci for murine malaria. For example, the identification of the Char4 region on mouse chromosome 3, which contains a number of possible candidate genes for malaria resistance, can now be used to search for possible associations of the corresponding human syntenic chromosomal region with susceptibility and/or severity of disease in endemic areas of malaria. 47 This new approach of combining murine and human genetics offers an extremely promising way of further exploring genetic variability in response to malarial infections.
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Evolutionary implications
As we have seen, a recurrent pattern is emerging for the distribution and molecular pathology of the human malaria-related polymorphisms. Despite the remarkable degree of protection offered against heterozygotes by the sickle cell gene, and its frequent appearance in Africa, the Middle East and India, it has never been found further east than India. Similarly, although Hb E reaches extremely high frequencies throughout Southeast Asia it is not seen further west than the eastern parts of the Indian sub-continent. Recent studies of the ␤-globin gene haplotypes associated with the ␤ S Senegal mutation have suggested that it is recent (45-70 generations) in origin. 48 Both the ␣-and ␤-thalassaemias occur throughout the tropical climes, with the exception of central and South America, but in each of the high frequency populations there are different sets of mutations; their relationships to haplotypes of the ␤-globin gene suggest that the expansion of the ␤-thalassaemia mutations must have occurred fairly recently. Indeed, all these observations are in keeping with the notion that whatever has been responsible for achieving the extraordinary high gene frequencies for these conditions has been of fairly recent origin.
Recent studies of haplotype diversity and linkage disequilibrium at the human G6PD locus provide further evidence of the recent origin of alleles that confer malarial resistance. 49 In an analysis of two G6PD haplotypes it was found that two common variants appeared to have evolved independently between 3000 and 11 000 years ago. These observations on the fairly recent, in evolutionary terms, appearance of genetic polymorphisms which confer resistance to malaria are in keeping with estimates of the spread of P. falciparum derived from studies of polymorphic systems of the parasite. For example, a recent analysis of 25 intron sequences of P. falciparum, involving both general metabolic and housekeeping genes, showed very few nucleotide polymorphisms and suggested that the parasite originated in something like its present form between 9 and 20 000 years ago. 50 These figures are in general agreement with other studies of polymorphic genes of P. falciparum. 51 This time-scale is in keeping with the notion that it was the development of agriculture somewhere between 5 and 10 000 years ago which provided the conditions necessary for the effective spread of malaria.
The picture that is emerging therefore is that during the relatively short exposure to severe forms of malaria by human populations, a wide range of different genetic polymorphisms have been utilised to modify individual response to this lethal disease. This has had a profound effect on the genetic constitution of these populations. Not only, as evidenced by the haemoglobin disorders and G6PD, has it left in its wake some extremely common monogenic diseases, but it may well have changed the capacity of these populations to respond to other infections. Clearly, we have only identified the tip of the iceberg of the remarkable genetic variation which exposure to malaria has left in its wake.
Genetic variation in response to other infectious organisms
The growing literature on genetic variation in response to bacteria, viruses, and parasites has been reviewed recently 1, 52 and is summarised together with key references in Table 1 . It is only possible to outline a few of the principles that are emerging from this field.
Several examples have been found of susceptibility to infectious agents conferred by a single gene in a Mendelian fashion.
1 Interestingly, some of these susceptibility effects are remarkably specific for particular microbial species. For example, families with deletions in the interferon-␥ receptor 1 gene show dominant susceptibility to opportunistic non-tuberculous mycobacterial and salmonella infections. On the other hand, there appears to be less increased risk to infections by tuberculosis or leprosy, for example.
There is growing evidence that polymorphisms of the HLA/DR gene complex may be involved in variable susceptibility or a resistance to a wide range of infectious diseases including tuberculosis, HIV/AIDS, hepatitis B and C, typhoid fever and leprosy.
1 Among these conditions there is a wide range of variability to which antigen-specific immune responses are HLA restricted. And it is becoming apparent that the HLA/DR system may only account for a small proportion of the hereditability of some of these responses, with non-HLA genes having a greater effect. But because there is also growing evidence for strong associations with autoimmune disease and particular variants of this system, the dissection of these complex relationships is becoming of increasing importance.
As in the case of malaria, a variety of polymorphisms relating to cytokines and immune effectors are involved in variable susceptibility to infectious agents (Table 1) . These relationships are well exemplified in the cases of the vitamin D receptor gene (VDR) and the gene for solute-carrier-family-11, member 1 (SLC11A1), until recently designated NRAMP1.
As well as its role in calcium metabolism the active metabolite of vitamin D is important for modulating immune responses, including suppression of lymphocyte proliferation, immunoglobulin production and cytokine synthesis. It also stimulates cell-mediated immunity, modifies dendritic cell maturation, and activates macrophages to inhibit M. tuberculosis in vitro. 1 A polymorphism of this gene is strongly associated with resistance to tuberculosis and modification of the course of leprosy and hepatitis B. 53, 54 In murine models, SLC11A1 has been found to be important in protection against several intracellular infections. In humans, variants of this gene have shown a modest association with tuberculosis in a wide range of different populations although the findings are not consistent between different races. 1 The observation that a variant in the promoter of the chemokine receptor 5 (CCR5) confers protection in homozygotes against HIV infection, and that heterozygotes have a delay in the progression to AIDS, has been extended and confirmed by many studies. 55 More recently, commoner CCR5 polymorphisms have been analysed. Homozygosity for another promoter polymorphism has been associated with increased rate of transmission of HIV to Afro-American infants 56 and several studies have shown that single nucleotide polymorphisms or their haplotypes in the promoter of CCR5 are associated with accelerated progression to AIDS. 57 Similar associations have also been found with another variant, CCR2Ile64. 58 Individuals who are homozygous for variants in SDF1 (stromal cell-derived factor 1), a ligand of chemokine receptor 4 that can down regulate its expression, also may have altered rates of progression to AIDS. 59 These examples of variation in genetic response to infection largely stem from work that has followed the analysis of particular candidate genes. Currently, there is a major interest in searching for susceptibility genes using whole-genome linkage analysis; promising results have been obtained in the cases of leprosy, tuberculosis, and chronic hepatitis. 1 Using the related sib-pair analysis approach, a susceptibility locus for Schistosoma mansoni has been defined on chromosome 5, in the region which contains a number of immune-related molecules including several cytokines. 60 Interestingly, this region has also shown linkage with phenotypes such as high IgE levels, atopy, asthma and various forms of dermatitis.
1
Comment
This rapidly evolving field is providing some remarkable information about the way in which the genetic constitution of human populations has been modified by past or present exposure to a wide variety of pathogens. And it is starting to yield tentative information about the timescales involved, at least in the case of the red cell polymorphisms related to varying susceptibility to malaria. While these findings are of considerable evolutionary interest, they may, in the long term, have more practical applications. If, for example, malaria vaccines are to be investigated in different populations, and particularly if the objective is attenuation rather than total protection, it will be important to know beforehand that a high proportion of the population has a genetic polymorphism which offers up to 60% protection against the most severe complications of the disease, as is the case in Papua New Guinea, for example. Whether the further investigation of the mechanisms of genetically determined resistance will provide novel approaches to the prevention or management of communicable diseases is not clear, though it remains a possibility that is well worth further exploration.
